Selective Inhibitors of G2019S-LRRK2 Kinase Activity
Author:
Affiliation:
1. ESCAPE Bio, South San Francisco, California 94080, United States
2. Aptuit, an Evotec Company, Verona 37135, Italy
3. WuXi AppTec, Tianjin 300456, P. R. China
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01243
Reference23 articles.
1. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
2. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
3. LRRK2: Cause, Risk, and Mechanism
4. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson’s Disease
5. LRRK2 in Parkinson disease: challenges of clinical trials
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Thioamides in medicinal chemistry and as small molecule therapeutic agents;European Journal of Medicinal Chemistry;2024-11
2. Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to date;Expert Opinion on Therapeutic Patents;2024-07-19
3. Synthesis, Crystal Structure, Hirshfeld Surface Analysis, and Computational Approach of a New Pyrazolo[3,4-g]isoquinoline Derivative as Potent against Leucine-Rich Repeat Kinase 2 (LRRK2);ACS Omega;2024-07-01
4. Concurrent Optimizations of Efficacy and Blood–Brain Barrier Permeability in New Macrocyclic LRRK2 Inhibitors for Potential Parkinson’s Disease Therapeutics;Journal of Medicinal Chemistry;2024-04-29
5. G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage;npj Parkinson's Disease;2024-03-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3